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Abstract
Background: The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased osteoclastogenesis
and osteoclast activity in bone. Here, we used a mixed osteolytic/osteoblastic murine model of bone-metastatic prostate
cancer, RM1(BM), to determine how inhibiting osteolysis with ZOL affects the ability of these cells to establish metastases in
bone, the integrity of the tumour-bearing bones and the survival of the tumour-bearing mice.
Methods: The model involves intracardiac injection for arterial dissemination of the RM1(BM) cells in C57BL/6 mice. ZOL
treatment was given via subcutaneous injections on days 0, 4, 8 and 12, at 20 and 100 mg/kg doses. Bone integrity was
assessed by micro-computed tomography and histology with comparison to untreated mice. The osteoclast and osteoblast
activity was determined by measuring serum tartrate-resistant acid phosphatase 5b (TRAP 5b) and osteocalcin, respectively.
Mice were euthanased according to predetermined criteria and survival was assessed using Kaplan Meier plots.
Findings: Micro-CT and histological analysis showed that treatment of mice with ZOL from the day of intracardiac injection
of RM1(BM) cells inhibited tumour-induced bone lysis, maintained bone volume and reduced the calcification of tumour-
induced endochondral osteoid material. ZOL treatment also led to a decreased serum osteocalcin and TRAP 5b levels.
Additionally, treated mice showed increased survival compared to vehicle treated controls. However, ZOL treatment did not
inhibit the cells ability to metastasise to bone as the number of bone-metastases was similar in both treated and untreated
mice.
Conclusions: ZOL treatment provided significant benefits for maintaining the integrity of tumour-bearing bones and
increased the survival of tumour bearing mice, though it did not prevent establishment of bone-metastases in this model.
From the mechanistic view, these observations confirm that tumour-induced bone lysis is not a requirement for
establishment of these bone tumours.
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Introduction
Some primary cancers have a high propensity to metastasise to
bone but the reasons for this remain unclear, although it is generally
accepted that growth of most cancers in bone is dependent on factors
present in the bone micro-environment. Tumour cells can induce
proliferation and activation of bone cells through release of growth
factors and this increase in activity causes further stimulation of the
cancer cells in what has been termed a ‘‘vicious cycle’’ [1]. Bone
involvement is common in prostate and breast cancers and myeloma,
and while breast cancer and myeloma bone-metastases are predom-
inantly osteolytic, involving increased osteoclast activity leading to
bone erosion, prostate cancer bone metastasis cases are heteroge-
neous, involving both bone lytic and sclerotic effects [2]. In osteolytic
lesions, cancer cells can produce cytokines that promote osteoclast
differentiation directly[3,4] and indirectlythrough stimulation of bone
marrow stromal cells to promote osteoclastogenesis [5]. Similarly,
tumour cells can produce cytokines that promote osteoblast activity
and induce bone growth [6] and osteoblasts can induce cancer
development and progression [7,8,9]. The interactions between the
tumour cells and bone cells dictate the bone metastatic phenotype.
Zoledronic acid (ZOL) and other bisphosphonates (BP) inhibit
the metastasis and growth of bone-resident tumours through
inhibiting osteoclast function. Thus ZOL inhibits the bone-
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bone turnover also slows the vicious cycle, resulting in a decrease
in bone-tumour size and, in some cases, the number of bone
lesions in various animal models of osteolytic bone cancer [10].
However, there have been contradictory reports of the effects of
ZOL on osteoblastic bone tumours. While ZOL treatment does
not inhibit intra-osseous growth of the osteoblastic cell line LAPC-
9 [11], the growth of intra-tibial LuCaP 23.1 cells is inhibited by
ZOL [12]. A subsequent study suggested that tumour-mediated
osteolysis is not required for osteoblastic metastases [11].
Here we use a mixed osteolytic/osteoblastic syngeneic mouse
model of prostate cancer metastasis to bone, the RM1 bone
metastatic (BM) model [13] to assess the impact of ZOL treatment
on the establishment of bone metastases, the integrity of tumour-
bearing bones and the overall survival of mice.
RM1(BM) cells injected intothe leftventricleof the heart result in
multiple bone metastases with few soft tissues tumours. We
demonstrate that inhibition of osteolysis with ZOL treatment does
not influence incidence of bony tumours. Nonetheless, ZOL
treatment did increase survival of mice in a manner that is dose
dependent. Most importantly, ZOL treatment also decreased the
lytic effects of the RM1(BM) tumours on bone as assessed by
histology and micro-computed tomography (micro-CT) analysis,
and appears to inhibit calcification of tumour-induced endochon-
dral bone, but not osteoid formation. We did not determine if ZOL
influenced the size or growth kinetics of tumours. The experiments
presented here employed intra-cardiac injection, which does not
causebone damage directly andtheresultingmetastatic foci inthese
experiments are likely to involve relatively few cells. Thus the
establishment ofmetastasesfromsingle cellsorsmallclusters ofcells,
a condition more likely to reflect natural metastatic events, does not
necessarily require initial lytic conditions.
Results
In the RM1(BM) bone metastasis model, ZOL treatment had a
significanteffectonthesurvivalofmicecomparedto untreatedmice
(Figure 1). Overall there was a trend of increased survival with
increased dose (p=0.012). Survival of mice in the 100 mg/kg dose
was significantly different from that of the vehicle treated group
(p=0.031) while the 20 mg/kg dose did not reach a statistically
significant difference from the control group with the sample sizes
employed in these experiments (p=0.108). The median survival
time for the vehicle-, 20 mg/kg ZOL- and 100 mg/kg ZOL-treated
mice was 14.5, 18.5 and 20 days respectively.
Osteocalcin levels were generally lower in tumour-bearing mice,
though the difference was not statistically significant and treatment
of these mice with 20 (p,0.01) or 100 mg/kg (p,0.01) of ZOL
further reduced the serum osteocalcin compared to the normal
controls (Figure 2A). The serum TRAP 5b levels of tumour-
bearing, untreated mice were similar to those of the controls.
However, treatment with 20 or 100 mg/kg of ZOL lowered the
serum TRAP 5b to less than 40% of the control mice and those
given the RM1(BM) cells only (p,0.001, Figure 2B).
The presence of tumour lesions in mice was evaluated by two
means, fluorescence imaging for green fluorescent protein (GFP)
expression by tumour cells followed by confirmation with histology
as described [13]. The RM1(BM) cell line was sensitive to ZOL
treatment in vitro (Data not shown), but the treatment had little
effect on the incidence of soft-tissue or bone tumours in this model.
ZOL treatment did not reduce the number of bony lesions nor the
number of tumour-metastases in soft tissue in the RM1(BM)
injected mice (Figure 3A–C). We did not assess the effect of the
ZOL treatment on the growth of established tumours.
Reconstructed three-dimensional images of bones from micro-
CT and representative H and E stained histological sections are
shown in Figure 4 and 5 respectively. The sections were also
Figure 1. Zoledronic acid treatment improves mouse survival
but does not reduce the number of metastases. (A) Kaplan-Meier
survival plot of mice given an intra-arterial injection of RM1(BM) cells
followed by treatment with the 100 mg/kg or 20 mg/kg zoledronic dosing
regimens or vehicle only as described in Materials and Methods. The log
rank test for trend indicates a trend of increased survival with increasing
dose (p=0.012), and a significant difference in survival between mice in
the 100 mg/kg dose group vs vehicle control groups (p=0.031, Kaplan-
Meier followed by Breslow pair-wise comparison using SPSS 17.0).
doi:10.1371/journal.pone.0019389.g001
Figure 2. Surrogate markers of bone metabolism in serum of
normal, tumor-bearing and zoledronic acid treated mice. (A)
Levels of the osteoblast marker, osteocalcin were reduced in serum of
zoledronic acid treated mice. (B) Tartrate-resistant acid phosphatase 5b,
an indicator of osteoclast activity, was also reduced with treatment.
Points on the graph represent serum levels for individual mice while
bars show the position of the means within each group. Statistical
analysis was performed using one-way ANOVA for analysis followed by
Tukey’s post test. *** p,0.001.
doi:10.1371/journal.pone.0019389.g002
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development from established/calcified bone (Figure 6). Mice with
metastatic bone lesions in the long bones showed significant bone
lysis, particularly near the epiphyseal plate, with a reduction in
trabecular bone (Figure 4B) compared to the normal controls
(Figure 4A). The lytic effect of the tumour is reduced in the 20 mg/
kg ZOL treatment group (Figure 4C) and perhaps more so in mice
given 100 mg/kg ZOL (Figure 4D). The micro-CT results are
confirmed by the histological results (Figure 5 and 6), showing
normal trabecular bone structure in the untreated control mice
(Figure 5A, 5B and 6A) but evidence of both lytic and sclerotic
effects in the untreated tumour-bearing bones (Figure 5C, 5D and
6B). ZOL treatment at 20 mg/kg preserved trabecular structure in
tumour-bearing bones (Figure 5E, 5F and 6C) and the 100 mg/kg
dose increased trabecular bone (Figure 5G, 5H and 6D). The
increase in tumour-induced endochondral trabecular bone
formation is particularly evident in the ZOL treated mice
(Figure 5E and 5G) due to the concomitant inhibition of
tumour-induced lysis. However, incomplete mineralization of
trabecular bone osteoid near the epiphyseal plate is evident in
the ZOL-treated tumour-bearing bones (Figure 6C and 6D).
Quantitative analysis of micro-CT data indicates that there was
no significant change in the surface area of the bones in normal,
tumour-bearing or treated bones (Figure 7A). The primary effect
of the tumour is the reduction in bone volume (p,0.01, Figure 7B)
and consequent increase in the bone-surface area: bone-volume
ratio in tumour-bearing bones (p,0.001, Figure 7C), while the
ZOL treatments result in an increase in bone volumes (p,0.001,
Figure 7B) and a decrease in bone-surface area: bone-volume ratio
(p,0.001, Figure 7C) of tumour-bearing bones.
Discussion
When injected by the intra-cardiac route, the RM1(BM) cell
line induces multiple bone metastases with relatively few (and
relatively small) soft tissue tumours [13]. Of note is the observation
that the resulting bony metastases do not show preference for
particular skeletal sites where high bone turnover occurs,
indicating that high bone turnover is not required for the
establishment of metastases. Furthermore the resulting bone
metastases have mixed osteolytic and osteoblastic characters with
neither phenotype predominating [13]. We determined that intra-
cardiac injection of RM1(BM) cells is an excellent model for
assessing if ZOL could inhibit the establishment of tumours
metastases which were not dependent upon lytic growth, that is,
the vicious cycle. We also assessed the ability of ZOL treatment to
inhibit the tumour-induced osteolysis and endochondral bone
formation and determined the influence of the treatment on the
overall survival of mice.
Like other nitrogen-containing BPs, ZOL induces apoptosis in
osteoclasts by inhibiting enzymes of the mevalonate pathway and
preventing the isoprenylation of small GTP-binding proteins such
as Ras and Rho [15,16]. In vivo, BPs bind with high affinity to bone
hydroxy-appatite and thus are sequestered by active osteoclasts in
high concentrations, leading to osteoclast apoptosis. Although a
number of other mechanisms including direct killing of cancer
cells, inhibition of angiogenesis and activation of cdT cells [17,18]
have been demonstrated for ZOL, its effect on osteoclasts remains
the main mechanism by which ZOL inhibits bone cancer under
current treatment regimens. The benefit to the patient is
potentially two-fold: ZOL inhibits the osteoclast-mediated lysis
induced by the tumour and so interrupts the vicious cycle and
subsequent promotion of tumour growth. This is certainly true of
osteolytic tumours, but the effects of ZOL treatment on tumours
that are not dependent upon bone lysis are poorly understood.
Treatment of tumour-bearing mice with ZOL prolonged the
survivalofmiceinourstudy(Figure1).Atthe 100 mg/kg dose,there
is a statistically significant increase in survival time compared to the
vehicle treated mice and a trend towards increased survival in the
20 mg/kg treated mice. Similar results have been reported for other
syngeneic cancer models [7,8,9]. However in osteolytic models of
multiple myeloma [10] and breast cancer [8], significant reduction
in establishment of bone metastatic lesions was observed, but this is
not true for our system (Figure 3).We havedemonstratedpreviously
[13] that the RM1(BM) cells metastasise to most skeletal sites and
thus metastasis of these cells to bony sites appears to be independent
of bone turnover rates. Thus, we are not surprised that the
inhibition of bone lysis by ZOL treatment has no demonstrable
effect on the establishment of tumours in bone. These findings
suggest that the predilection of the RM1(BM) cells for bone is
dependent upon other factors, potentially an increased homing to
bony sites or dependence upon factors independent of bone lysis.
Although this is a mixed osteolytic/osteoblastic model, the results
are in contrast to those of Corey [12], but similar to results achieved
with the osteoblastic cells line, LAPC-9 [11].
We have assessed the concentrations of the two bone turnover
markers, osteocalcin (secreted by osteoblasts) and TRAP 5b
Figure 3. Zoledronic acid treatment did not reduce establish-
ment of metastases in RM1(BM) injected mice. (A) Total number
of metastases, (B) bone-metastases, or (C) soft tissue metastases as
assessed by one-way ANOVA. Each point represents the number of
metastases in an individual mouse, bars indicate the median within the
group.
doi:10.1371/journal.pone.0019389.g003
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19389Figure 4. Zoledronic acid preserves bone structure. MicroCT scans of mouse femur and tibia; normal control (A), RM1(BM) tumour-bearing (B),
RM1(BM) tumour-bearing treated with the 20 mg/kg ZOL regimen (C), RM1(BM) tumour-bearing treated with the 100 mg/kg ZOL regimen (D).
doi:10.1371/journal.pone.0019389.g004
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treatment decreases the serum levels of both these markers
(Figure 2) indicating that ZOL has inhibited both osteoclast and
osteoblast activity at the systemic level. These results are in
agreement with previous reports of decreased osteocalcin in breast
cancer patients [19] and a TRAP 5b decrease in mice [20]
Figure 5. Histological analysis of the effects of zoledronic acid-treatment on normal and tumour-bearing bones. H&E stained sections
of the femoral head at 40X (A, C, E and G) and 120X (B, D, F and H) magnification showing normal (A&B) and RM1(BM) tumour bearing bones (C–H);
Typical examples of bones from untreated mice (A–D) and mice treated with 20 mg/kg ZOL (E&F) or 100 mg/kg ZOL (G&H) are shown. T=tumour,
Arrow=Trabecular bone.
doi:10.1371/journal.pone.0019389.g005
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and osteoclast activity are impaired suggests that the observed
increase in bone volume and surface area with ZOL treatment
(Figure 7) is a result of reduced osteoclast activity, rather than
increased osteoblast activity. However, we find it particularly
interesting that the osteocalcin levels in serum are decreased in
ZOL treated tumour-bearing mice attendant with the observation
of increased endochondral osteoid formation in these mice
(Figure 5 F and H). Importantly, the new osteoid material
observed in the ZOL treated mice appears largely un-calcified
(Figure 6C and 6D), particularly at the high dose (Figure 6D), at
the time when the mice were killed suggesting an uncoupling of the
osteoid development and calcification steps of bone formation. Of
relevance is the observation that osteocalcin-deficient mice have
increased bone formation [21]. The decrease in trabecular bone
calcification with increased in ZOL dose is a novel finding and
appears to contradict the extensive existing literature on the effects
of bisphosphonates on bone. However, we also show that ZOL
treatment of tumour bearing mice increases the bone volume of
mouse leg bones (Figure 7B), which supports previous findings. In
similar preclinical studies using the C4-2 [21] and LuCaP 23.1
[22] xenograft models, ZOL treatment was also shown to increase
the overall bone volume. Thus, the decreased mineralization of
newly formed trabecular bone observed here is consistent with an
overall preservation of existing mineralized bone in tumour
bearing mice. These effects of ZOL in maintaining bone integrity
are associated with increased survival in ZOL treated mice.
The effects of ZOL on the bone structure may or may not
directly affect the progression of the cancer, but prevention of
abnormal bone modeling in a tumour-ridden bone may be key to
ZOL reducing the risk of skeletal related complications and
prolonging the time to skeletal related event occurrence in patients
with bone-metastatic prostate cancer [23,24]. Furthermore, ZOL
treatment has significant implications for dealing with pain
reduction in the clinic. BPs improve the bone structure in patients,
with a major reduction in related pain [25,26,27], which has been
attributed to the re-calcification of the bone, that has led to a
decrease in analgesic usage. Of relevance is the observation in
multiple myeloma (an osteolytic disease) patients, decreased
osteocalcin levels, as reported here, was related to reduction in
Figure 6. Histological analysis with tetrachrome stain for effects of zoledronic acid-treatment on normal and tumour-bearing
bones. Tetrachrome stain for differentiation of mineralised and unmineralised bone at 120x magnification Normal (A), or RM1(BM) tumour bearing
bones (B–D). (A&B) Untreated, (C) 20 mg/kg ZOL (D) 100 mg/kg ZOL. T=tumour, Arrow=Trabecular bone.
doi:10.1371/journal.pone.0019389.g006
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effective therapy for mixed osteoblastic/lytic tumours as it
increases survival of treated mice. The treatment inhibits bone
lysis and reduced osteoclast activity as expected. ZOL treatment
also reduced serum levels of osteocalcin, but did not inhibit tumour-
induced endochondral osteoid formation although it partially
inhibited subsequent calcification of this osteoid material in a
dose-dependent manner. ZOL did not reduce the frequency of
metastasesindicating that althoughRM1(BM) tumoursinducebone
lysis, establishment of tumours is not dependent upon lytic growth.
Materials and Methods
Ethics statement
The University of New South Wales Animal Care and Ethics
Committee approved animal housing, husbandry, and all
experimental procedures performed on animals prior to experi-
ments (Project application approval number: 05/120B). Mice were
monitored closely (on a daily basis) and euthanased according to
predefined criteria (loss of 20% of body weight, significant loss of
condition, or partial paralysis) as approved by the animal ethics.
Cell culture
RM1 cells were obtained from Dr. T Thompson, Baylor College,
and RM1(BM) was developed by serial passaging of RM1 in vivo
[13]. Both cell lines were cultured under standard conditions (37uC
in a 5% CO2 incubator) in DMEM (Invitrogen, Melbourne,
Australia) with 10% FBS (Invitrogen) and L-glutamine (Invitrogen).
Surrogate Markers of Bone Metastasis in Serum
Sera from tumour-cell injected mice and normal control mice
collected at necropsy by cardiac puncture were assessed for the
presence of surrogate markers of bone metabolism. Insufficient
serum was available from some mice for assessing surrogate
markers. Osteocalcin content was assessed using an osteocalcin
enzyme-linked immunosorbent assay (ELISA) (Biomedical Tech-
nologies Inc., Stoughton, MA) according to the manufacturer’s
instructions. Tartrate-resistant acid phosphatase (TRAP) 5b
concentration was determined by the MouseTRAP assay (Suomen
Bioanalytikka Oy, Turku, Finland) as proscribed in the kit. Serum
protein levels were determined by comparison to a standard curve
prepared from standards provided with the assays.
Animals
5–6 week old C57BL/6 mice were obtained from the Animal
Resource Centre (Adelaide, Australia). They were housed and
maintained at the Biological Resources Centre, Little Bay, NSW.
On day 0 of the experiment, mice were injected with either of
3610
4 RM1(BM) cells in saline or saline alone (100 ml) into the left
ventricle of the heart. Mice were treated on days 0, 4, 8 and 12 via
subcutaneous injection of either 20 mg/kg or 100 mg/kg of
zoledronic acid (Novartis Pharmaceuticals, Australia), or saline
(vehicle). The cumulative dose at 20 mg/kg equates to an
approximate single dose of 4 mg in patients. Mice were monitored
closely and euthanased according to predefined criteria (loss of
20% of body weight, significant loss of condition, or partial
paralysis) as approved by the animal ethics. The number of
tumours in each mouse was assessed by GFP fluorescence (as
described previously [13]) at necropsy followed by histology. The
presence of only a thoracic tumour is an indication that the IC
injection was not successful and therefore such mice were excluded
in these assessments.
Histology
The mouse carcasses were fixed in 10% formalin in phosphate-
buffered saline (PBS) for 48 h then decalcified in 10% EDTA for
10–14 days. Decalcified fore and hind limbs were embedded in
paraffin after tissue processing (dehydration, clearance and
impregnation). Sections (5 mm) were cut from each block and
stained with Harris’ Hematoxylin and Eosin (H&E). For analysis of
mineralization of the bone, sections (8 mm) were cut and stained
with tetrachrome stain according to previously published methods
[14] with slight modifications: the ponceau red solution was
replaced with Briebrich Scarlet/Acid Fuchsin solution. Sections
were examined with the Aperio Scanscope XT (CA, USA) and
images taken with Imagescope Viewer (Aperio, CA, USA).
Micro-CT scanning and analysis
After formalin fixation, the hind limbs were selected for micro-
CT scanning before processing for histology. Tumour-bearing
limbs were identified prior by expression of GFP in vivo. For
Figure 7. Zoledronic acid treatment alters bone volume and
the bone surface-area:volume ratio in normal and tumour-
bearing bones. There was no significant change in bone surface area
(A) induced by the presence of a tumour or treatment with zoledronic
acid. However, bone volume was dramatically reduced in RM1(BM)
containing bones and the treatment with ZOL prevented this loss in a
dose-dependent manner (B), resulting in lower surface area/volume
ratio (increased bone density) compared to normal or tumor-bearing
bones (C). Results are based on measurements obtained from CT scans
as described in Materials and Methods section. Statistical analysis was
performed by one-way ANOVA followed by Tukey’s post test, * p,0.05,
** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0019389.g007
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right and left hind legs of five mice were scanned. For other
treatment groups, only a single leg was scanned from each mouse.
All analysed bones were from animals that were culled between
day 15 and 21 after injection of the cells. Scanning and
reconstruction was performed using a Skyscan 1072 micro-CT
system and associated software (Skyscan, Antwerp, Belgium).
While maintaining the specimen in the field of view during the
image acquisition, the sample was rotated 180u around the vertical
axis. Images were exposed for 5.9 sec and projections recorded at
each rotational step, every 0.9u, at 80 keV and 100 mA. Cross
sectional images (DICOM format) were generated from the
projected CT images using Nrecon (Skyscan, Belgium). Bone
surface area and volume were calculated from DICOM images
using the manufacturer’s software (CT-Analyzer, Skyscan, Bel-
gium). The region of the leg around the knee joint from the apex
of the third trochanter of the femur to the bifurcation of the tibia
and fibula was selected for this analysis to ensure consistency.
Reconstruction of the 3D model and image visualisation was
performed using ANT software (Skyscan, Belgium).
Statistical analysis
One-way ANOVA followed by Tukey’s post tests were
performed using GraphPad Prism version 4.00 for MacIntosh,
GraphPad Software (San Diego, USA). Survival was assessed by
Kaplan-Meier followed by Breslow pair-wise comparison using
SPSS 17.0.
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